Chu-Chi Liu

Chairman
Ever Supreme Bio Technology Co.,Ltd

​​

Chairman Chu-Chi Liu graduated from the School of Medicine at Yang-Ming University and has served as a clinical researcher at Yale University in the United States. With 35 years of experience in clinical medicine and genetic counseling, he previously held the position of Director of the Cell Laboratory at Taichung Veterans General Hospital. Chairman Liu has long been concerned with issues related to cell therapy and recognizes the importance of immune cell and stem cell therapies as significant trends in future medical developments. In 2016, he invited colleagues from the medical field to collaborate in establishing a new cell therapy pharmaceutical company. In December 2016, he founded Ever Supreme Bio Technology Co., LTD and has served as Chairman since then. Under Chairman Liu's leadership, Ever Supreme became the first company primarily engaged in cell therapy to be listed on the stock market in January 2021.

Company Profile

Ever Supreme has been established for approximately 7 years, focusing on the cell therapy market and unmet medical needs. It possesses two major technological platforms: immune cells and stem cells. Ever Supreme is engaged in the research and development of novel drugs for immune cell therapy and stem cell therapy, particularly targeting severe diseases. With its advanced cell therapy equipment, expertise, and technology, the company aims to apply its new drug development products to the medical market at an early stage. By providing diverse and customized cell therapy products, Ever Supreme has become the leading biotechnology company in Taiwan, with over 600 patients treated with cell therapy. This has contributed to the growth of Taiwan's cell industry. Ever Supreme currently holds a clear leading position and envisions expanding its new drug cell therapy products globally in the future, making Taiwan's cell therapy visible to the world.

​​